Robert B. Kay

Executive Chairman and Chief Executive Officer

Robert B. Kay is our Executive Chairman and Chief Executive Officer and has served in these capacities since we became a publicly traded company in August 2008. Previously, Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer & Boose LLP, with a particular focus on mergers and acquisitions and joint ventures. Mr. Kay received his B.A. from Cornell University's College of Arts & Sciences and his J.D. from New York University Law School. Mr. Kay oversees every aspect of our business in his role as executive chairman and chief executive officer. Given his years with the company and his prior experience, we believe that Mr. Kay has an excellent understanding of our business and the global markets in which we operate and those in which we anticipate operating in the future.

Robert L. Erwin


Robert L. Erwin previously led Large Scale Biology Corporation from its founding in 1988 through 2003, including a successful initial public offering in 2000, and continued as non-executive Chairman until 2006. Mr. Erwin recently served as Managing Director of Bio-Strategic Directors LLC providing consulting services to the life sciences industry. He served as Chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. He is currently Chairman of Novici Biotech, a private biotechnology company and a Director of Resolve Therapeutics LLC. Mr. Erwin's non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is co-founder and President of the Marti Nelson Cancer Foundation, and a member of the Cancer Policy Forum of the Institute of Medicine. Mr. Erwin received his B.S. degree with Honors in Zoology and an M.S. degree in Genetics from Louisiana State University.

R. Barry Holtz, Ph.D.

President, iBio CDMO

Dr. Holtz has 30 years of experience in the development of bioproducts and biopharmaceuticals and design of biopharmaceutical manufacturing facilities. Dr. Holtz led the design/build team for construction and commissioning of the current iBio facility.

Serving 15 years as Senior Vice President for Large Scale Biology Corporation, Dr. Holtz was responsible for the product development, clinical development and manufacturing compliance of the company's proprietary therapeutics portfolio. Dr. Holtz led a team that developed and produced a recombinant, plant-made, patient-specific vaccine for the treatment of indolent Non-Hodgkin's Lymphone from the bench to human clinical trials. Dr. Holtz has led the development of three other Greenfield facilities and several smaller biotherapeutics production facilities.

Prior to Large Scale Biology, Dr. Holtz was the founder and President of Holtz Bio-Engineering. The company developed bioreactor based processes for the biotechnology sector and developed a proprietary line of bioreactors and distributed logic control systems for cell culture. Holtz Bio-Engineering was merged into Large Scale Biology in 1989.

Dr. Holtz received his Ph.D. at Pennsylvania State University and was an NSF Postdoctoral Fellow at Scripps Institution of Oceanography. Dr. Holtz has been awarded 23 US patents and has published over 60 scientific papers. Dr. Holtz was awarded the Pennsylvania State University, Outstanding Alumni Award in 2003.

James P. Mullaney

Chief Financial Officer

James P. Mullaney has over 20 years of experience encompassing finance, accounting, management and advisory positions. He has been a member of PwC's Audit practice as well as KPMG's CFO Advisory Services practice. Prior to joining iBio, Inc., Mr. Mullaney served in the capacity as Corporate Controller for Citihub Consulting, a multi-national IT services firm. He brings extensive finance transformation, strategic development and partnership, internal control and regulatory compliance background to iBio, Inc. He holds a CPA license in New York State.

Terence E. Ryan, Ph.D.

Chief Scientific Officer

Terence E. Ryan, Ph.D. is a pharmaceutical and biotech research leader who is highly accomplished in recombinant protein expression, and also has a record of innovation in cell biology, proteomics, and systems biology. His distinguished 20-year career includes working for such industry leaders as Wyeth (Pfizer) Research, GlaxoSmithKline, Celera Genomics, and Regeneron Pharmaceuticals. Dr. Ryan holds an M.S. and Ph.D. in Microbiology from Rutgers University, and received his AB in Biology from Princeton University.

James Abbey, Ph.D.

Vice President of Strategic Business Development

Prior to joining iBio, Dr. Abbey served as the Director for Global and Corporate Partnerships for the Texas A&M University System, where he established and managed key collaborations with major global organizations across industry and academia, drawing in more than $100 million in research funding to support the University System’s research initiatives. He also previously served as the International Strategic Collaborations Adviser and Director for the Texas/UK Collaborative & International Collaboration at Swansea University in Wales, United Kingdom. In that role, he helped establish Europe’s first Center for NanoHealth and led the creation of the Texas/UK Research Collaborative & International Collaboration, which brings together leading medical research institutions from the United Kingdom and Texas to harness their collective experience and excellence for the sake of continued innovation and development.

Dr. Abbey holds a Ph.D. in Nanotechnology from Swansea University in Wales United Kingdom, a M.B.A. from the University of Wales, United Kingdom, and a B.S. from the University of North Texas.  He also holds research affiliations with Houston Methodist Hospital Research Institute as Assistant Affiliate Member and is an Adjunct Professor in the College of Veterinary Medicine at Texas A&M University.

Wayne P. Fitzmaurice, Ph.D.

Vice President, Intellectual Property

Wayne P. Fitzmaurice, PhD. has extensive experience in plant biotechnology research, and is a USPTO certified Patent Agent. He led research teams at Biosource Technologies (later Large Scale Biology Corp.) for 15 years from 1992 to 2007 ultimately holding the position of Senior Director of Plant Biology and Pharmaceutical Development. He is a founding partner of Novici Biotech, and functions as their Senior Director of Intellectual Property. With Novici he is on key patents as both an inventor and a prosecuting patent agent. He also acted as an independent consultant in biotechnology intellectual property for several corporations. Dr. Fitzmaurice received a Ph.D. in Biochemistry from The Johns Hopkins University, and did postdoctoral research at the University of Wisconsin-Madison and North Carolina State University.